Up-regulating relaxin expression by G-quadruplex interactive ligand to achieve antifibrotic action.
Myocardial fibrosis is a key pathological change in a variety of heart diseases contributing to the development of heart failure, arrhythmias, and sudden death. Recent studies have shown that relaxin prevents and reverses cardiac fibrosis. Endogenous expression of relaxin was elevated in the setting of heart disease; the extent of such up-regulation, however, is insufficient to exert compensatory actions, and the mechanism regulating relaxin expression is poorly defined. In the rat relaxin-1 (RLN1, Chr1) gene promoter region we found presence of repeated guanine (G)-rich sequences, which allowed formation and stabilization of G-quadruplexes with the addition of a G-quadruplex interactive ligand berberine. The G-rich sequences and the G-quadruplexes were localized adjacent to the binding motif of signal transducer and activator of transcription (STAT)3, which negatively regulates relaxin expression. Thus, we hypothesized that the formation and stabilization of G-quadruplexes by berberine could influence relaxin expression. We found that berberine-induced formation of G-quadruplexes did increase relaxin gene expression measured at mRNA and protein levels. Formation of G-quadruplexes significantly reduced STAT3 binding to the promoter of relaxin gene. This was associated with consequent increase in the binding of RNA polymerase II and STAT5a to relaxin gene promoter. In cardiac fibroblasts and rats treated with angiotensin II, berberine was found to suppress fibroblast activation, collagen synthesis, and extent of cardiac fibrosis through up-regulating relaxin. The antifibrotic action of berberine in vitro and in vivo was similar to that by exogenous relaxin. Our findings document a novel therapeutic strategy for fibrosis through up-regulating expression of endogenous relaxin.
Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.
Hui-Ping
HP
Gu
Sen
S
Lin
Ming
M
Xu
Hai-Yi
HY
Yu
Xiao-Jun
XJ
Du
You-Yi
YY
Zhang
Gu
G
Yuan
Wei
W
Gao
D000818:Animals; D001599:Berberine / Q000494:pharmacology* / Q000627:therapeutic use*; D015153:Blotting, Western; D002478:Cells, Cultured; D047369:Chromatin Immunoprecipitation; D002942:Circular Dichroism; D004719:Endomyocardial Fibrosis / Q000378:metabolism* / Q000628:therapy*; D004797:Enzyme-Linked Immunosorbent Assay; D054856:G-Quadruplexes / Q000187:drug effects*; D006801:Humans; D008297:Male; D018613:Microscopy, Confocal; D011401:Promoter Regions, Genetic / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D012065:Relaxin
D001599:Berberine; D012065:Relaxin